Q2 2026 13F · SEC CIK 1483234
Crcm LP
Hedge fundFiled 2026-08-18 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $151.9M
- Reported positions
- 12
- Top holdings a year, 3 yrs
- +43.1%
- Average holding period
- 1.7 yrs
Crcm LP is a hedge fund that reported 12 positions worth $151.9M in its Q2 2026 13F, filed 2026-08-18. Its largest holdings were Ishares Gold Tr (IAU, 65.3%), Ishares Bitcoin Trust ETF (IBIT, 6.7%), Atrium Therapeutics Ord (RNA, 5.7%). A portfolio copying its top holdings returned 43.1% a year over the last 3 years, against 18.4% for the S&P 500.
Crcm LP holdings all 12 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| IAUIshares Gold Tr | 65.3% | +5.1% | $99.2M |
| IBITIshares Bitcoin Trust ETF | 6.7% | — | $10.1M |
| RNAAtrium Therapeutics Ord | 5.7% | — | $8.6M |
| AIFCAi Financial Corp | 4.9% | +0.7% | $7.4M |
| PLBYPlby Group Inc | 4.6% | +32.5% | $7.0M |
| BTGOBitgo Holdings Inc | 4.5% | — | $6.8M |
| SGOVIshares Tr | 3.1% | — | $4.8M |
| VZLAVizsla Silver Co | 1.8% | — | $2.8M |
| BNRBurning Rock Biotech Ltd-Adr | 1.2% | -24.8% | $1.8M |
| PCAPProcap Acquisition Corp. | 1.1% | +5.4% | $1.7M |
| PCSCPerceptive Capital Solution Cl A Ord | 0.7% | -16.3% | $1.1M |
| TRAXFirst Tracks Biotherapeutics | 0.5% | — | $711K |
What Crcm LP bought and sold in Q2 2026, against Q1 2026.
New positions
- IBIT Ishares Bitcoin Trust ETF6.7% of 13F
- RNA Atrium Therapeutics Ord5.7% of 13F
- BTGO Bitgo Holdings Inc4.5% of 13F
- SGOV Ishares Tr3.1% of 13F
- VZLA Vizsla Silver Co1.8% of 13F
- TRAX First Tracks Biotherapeutics0.5% of 13F
Added to
- PLBY Plby Group Inc+32.5% shares
- PCAP Procap Acquisition Corp.+5.4% shares
- IAU Ishares Gold Tr+5.1% shares
Reduced
- BNR Burning Rock Biotech Ltd-Adr-24.8% shares
- PCSC Perceptive Capital Solution Cl A Ord-16.3% shares
Sold out
- STAA Staar Surgical Cowas 1.3%
- USBC Usbc Incwas 0.2%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +32.7% /yr
- S&P 500 +20.1%
- 3 years
- +43.1% /yr
- S&P 500 +18.4%
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $151.9M | 12 |
| Q1 2026 | $141.2M | 8 |
| Q4 2025 | $296.0M | 11 |
| Q3 2025 | $345.7M | 10 |
| Q2 2025 | $336.6M | 9 |
| Q1 2025 | $245.3M | 6 |
| Q4 2024 | $245.9M | 6 |
| Q2 2024 | $138.3M | 6 |
| Q1 2024 | $132.9M | 6 |
| Q3 2014 | $12.3M | 7 |
| Q2 2014 | $15.6M | 11 |
| Q1 2014 | $36.1M | 14 |
Questions about Crcm LP's portfolio
What stocks does Crcm LP own?
Crcm LP's latest 13F, for Q2 2026 and filed Aug 18, 2026, lists 12 positions worth $151.9M. The largest are Ishares Gold Tr (IAU) at 65.3%, Ishares Bitcoin Trust ETF (IBIT) at 6.7%, Atrium Therapeutics Ord (RNA) at 5.7%, Ai Financial Corp (AIFC) at 4.9% and Plby Group Inc (PLBY) at 4.6%.
What did Crcm LP buy last quarter?
In Q2 2026, Crcm LP added a new position in Ishares Bitcoin Trust ETF (IBIT), a new position in Atrium Therapeutics Ord (RNA), a new position in Bitgo Holdings Inc (BTGO), a new position in Ishares Tr (SGOV), a new position in Vizsla Silver Co (VZLA), Plby Group Inc (PLBY) (+32.5% shares), Procap Acquisition Corp. (PCAP) (+5.4% shares) and Ishares Gold Tr (IAU) (+5.1% shares), compared with its Q1 2026 filing.
What did Crcm LP sell last quarter?
In Q2 2026, Crcm LP sold all of Staar Surgical Co (STAA), sold all of Usbc Inc (USBC), Burning Rock Biotech Ltd-Adr (BNR) (-24.8% shares) and Perceptive Capital Solution Cl A Ord (PCSC) (-16.3% shares), compared with its Q1 2026 filing.
How has Crcm LP's portfolio performed?
A portfolio copying Crcm LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +43.1% a year over the last 3 years, against +18.4% for the S&P 500. Over 1 year: +32.7% against +20.1%.
When is Crcm LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. Crcm LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.